GE HealthCare posts strong Q3 with 6.2% revenue growth and raises 2026 outlook

GE HealthCare Technologies reported solid third-quarter results with 6.2% organic revenue growth and margin expansion driven by broad-based demand. Growth opportunities arise from Pharmaceutical Diagnostics and Flyrcado, while the SOFIE acquisition is expected to boost radiopharmaceutical capabilities and future revenues. The company raised its 2026 guidance, forecasting 4% organic revenue growth, adjusted EPS between $4.95 and $5.05, and free cash flow of at least $1.6 billion. Despite a discounted valuation at 15.1 times forward earnings, investors should watch debt levels, acquisition execution, and the sustainability of recent cash flow improvements.

GE HealthCare Technologies holds a market cap of $34.28 billion and an enterprise value of $41.86 billion as of Oct 29, 2026, 17:11 WIB. The stock price is USD 75.90, showing a slight 0.11% increase on the day, with a dividend yield of 0.21%. Trading volume reached 9,566,604 shares, indicating active investor interest alongside the company's recent growth and raised guidance.